Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

about

Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance.Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells.

P2860

Q38716908-130035F9-FC9B-47F5-A8FB-11294E2520EC Q51334063-D4507260-F138-4FD9-A56D-DA86F7A70CD3

P2860

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

Item

http://www.wikidata.org/entity/Q43134812

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@en

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@nl

type

Item

label

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@en

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@nl

prefLabel

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@en

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@nl

P1476

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

@en

P2093

Belamy B Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Mechanism of fenretinide (4-HPR)-induced cell death

Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

Neuroblastoma: biological insights into a clinical enigma.

Retinoids and their receptors in cancer development and chemoprevention.

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

P304

212-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.5306/WJCO.V6.I6.212

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286640356

http://www.w3.org/2001/XMLSchema#string

P698

26677433

http://www.w3.org/2001/XMLSchema#string

P932

4675905

http://www.w3.org/2001/XMLSchema#string

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

about

P2860

P2860

Combination therapies improve the anticancer activities of retinoids in neuroblastoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932